Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Systemic sclerosis is a generalized autoimmune connective tissue disease of unknown aetiology. Profound vascular and immunological dysregulations result in tissue fibrosis affecting the skin and internal organs. Currently, two main clinical subtypes are distinguished, i.e. limited and diffuse cutaneous systemic sclerosis, which differ significantly in the clinical course and prognosis. Autoantibodies against topoisomerase (Scl-70), centromere-associated proteins, and nucleolar antigens are important for the diagnosis of the disease and give clues for its clinical manifestations and prognosis (prognostic autoantibodies). For most of these antibodies, however, the role in pathogenesis is not established. Anti-centromere antibodies are associated with limited cutaneous involvement and risk for pulmonary hypertension, whereas anti-topoisomerase I is associated with diffuse progressive disease and severe interstitial lung disease. Anti-Th/To positivity is associated with limited skin involvement but a high risk for severe internal organ involvement (Kidneys, PAH, Lung fibrosis). Anti-RNA polymerase I/III antibodies are associated with a high risk for renal involvement. Autoantibodies against the PDGF receptor and fibrillin-1 seem to play important roles in the pathogenetic process of systemic sclerosis.
Grassegger
Alfred
A
Dermatology, Phlebology and Laser Medicine, Salurner Strasse 15, Innsbruck, Austria. skin@drgrassegger.at
Pohla-Gubo
Gabriela
G
Frauscher
Margret
M
Hintner
Helmut
H
D000974:Antibodies, Antinuclear / Q000097:blood; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D002466:Cell Nucleolus / Q000276:immunology; D002503:Centromere / Q000276:immunology; D004264:DNA Topoisomerases, Type I / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D000071838:Fibrillin-1; D000071837:Fibrillins; D005455:Fluorescent Antibody Technique; D006801:Humans; D015151:Immunoblotting; D007122:Immunoelectrophoresis; D008840:Microfilament Proteins / Q000276:immunology; D011379:Prognosis; D017479:Receptors, Platelet-Derived Growth Factor / Q000276:immunology; D012307:Risk Factors; D045743:Scleroderma, Diffuse / Q000276:immunology; D045745:Scleroderma, Limited / Q000276:immunology; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000209:etiology / Q000276:immunology*; D054392:Adipokines
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D001324:Autoantigens; D004264:DNA Topoisomerases, Type I; D000071838:Fibrillin-1; D000071837:Fibrillins; D008840:Microfilament Proteins; D017479:Receptors, Platelet-Derived Growth Factor; C000605722:FBN1 protein, human; D054392:Adipokines